TDC
ELGX

Thompson Davis & Co’s Endologix Inc ELGX Stock Holding History

Thompson Davis & Co’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25
Closed -$3K – 1221
2016
Q2 		$3K Buy
+25
New +$2.87K ﹤0.01% 915
2014
Q1 		– Sell
-13
Closed -$2K – 884
2013
Q4 		$2K Buy
+13
New +$2.23K ﹤0.01% 671

Other funds holding ELGX

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Thompson Davis & Co's ELGX Position: Q3 2016 in Review

Thompson Davis & Co sold out of Endologix Inc (ELGX) in Q3 2016, closing a stake of 25 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in ELGX in Q4 2013 and held it in 2 quarters. The position peaked at $3K in Q2 2016. 152 funds tracked by Wall St. Rank hold ELGX as of Q3 2016.

  • Thompson Davis & Co reported no remaining Endologix Inc position as of Q3 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 25 Endologix Inc shares in Q3 2016, an estimated $3K.
  • Thompson Davis & Co first reported a position in Endologix Inc in Q4 2013 and held it in 2 quarters.
  • Thompson Davis & Co's Endologix Inc position peaked at $3K in Q2 2016.
  • 152 funds tracked by Wall St. Rank held Endologix Inc as of Q3 2016.

Based on Thompson Davis & Co's 13F filing for Q3 2016, filed 8 Nov 2016.